Insurance brokerage + enterprise new model, SIPAI HEALTH's strategic transformation highlights?

With the aggravation of the aging population trend and the continuous promotion of the construction of a multi-level medical security system, commercial health insurance is playing an increasingly important role. According to data from the Insurance Association, driven by policy support and market demand, the scale of commercial health insurance business continues to expand, and the variety of products is increasingly diverse. Over the past decade, the compound annual growth rate of commercial health insurance has exceeded 20%, with over 11,000 medical insurance products on sale. At the policy level, the government work report for 2026 mentioned "commercial health insurance" in two places for the first time. Not only did it list the "launch of an innovative drug catalog for commercial health insurance" as an important outcome for 2025, it also explicitly proposed to "accelerate the development of commercial health insurance". The report emphasizes that commercial health insurance should be linked with innovative drugs and medical devices, which means that commercial insurance will be deeply integrated into the national pharmaceutical innovation and medical payment system. Its role is shifting from a simple "payment provider" to an "innovative collaborative partner" and "system builder" at an accelerated pace. Under the policy guidance, a profound industrial transformation is taking place. In recent years, the cooperation between the insurance industry and the medical and healthcare field has deepened, with many insurance institutions accelerating their layout in the health and wellness field. The combination of insurance products with health and wellness services, as well as medical and pharmaceutical services, has become a new trend in the industry. In this wave, SIPAI HEALTH (00314), which precisely enters the niche market of corporate health insurance and corporate health management, is strategically transforming its business to deeply integrate insurance services with medical and pharmaceutical services, focusing on creating an integrated service ecosystem of "insurance, health, medicine, and wellness". Recently, SIPAI HEALTH announced its annual report for 2025. Although the decline in revenue reflects the company's pains during the strategic transformation period, the financial data reveals a deeper optimization of business structure and a significant improvement in quality after "cutting the fat", demonstrating broad development prospects. Reducing the number of business structures resulted in a decrease in total revenue, but core business volume and quality increased simultaneously The 2025 financial report shows that although total revenue has declined, SIPAI HEALTH's profitability has significantly improved, with cash flow and financial structure remaining steady, creating a clear contrast. Specifically, while the company's total revenue reached 2.071 billion yuan, the extent of losses significantly narrowed, with a normalized net loss of 47.57 million yuan, a 62.6% reduction from 2024; the overall gross profit margin increased from 8.5% in 2024 to 15.0%, a rise of 6.5 percentage points. At the same time, the company's operating cash flow turned positive, achieving a net amount of 6.355 million yuan, a significant improvement from -59.45 million yuan in 2024; holding a total of 932 million yuan in cash and specific financial assets, without external borrowing, demonstrating a stable financial structure and ample cash flow. This "contrast" in the financial report is a result of the company's "cutting the fat" approach to business structure - focusing on core business of corporate health insurance, while implementing structural reorganization of low-margin businesses such as specialty drug pharmacies. This shift towards high-margin sectors has yielded significant results. The company's core business performed excellently, achieving rapid growth in scale: by the end of 2025, revenue from corporate insurance business grew by 32% to 90.71 million yuan, with managed premium fees increasing by 47.8% year-on-year to 1.09 billion yuan; the number of service enterprises increased by 30.0% to 619; and the number of members exceeded 2.04 million, a YoY increase of 79.2%. Particularly noteworthy is the premium renewal rate of 101.5%, fully proving the high viscosity of the company's services and the high recognition of its customers, indirectly confirming the sustainability of SIPAI HEALTH's profit growth. Similarly, the Doctor Research Assistance (SMO business) segment presented solid results, with revenue growing by 16.3% to 462 million yuan, reinforcing its leading position in the industry. As of now, 1,153 SMO projects have been completed, with 852 ongoing projects; 20 new drugs have been launched in China, 2 in the US, and 1 in the EU throughout the year; the client base covers all top ten listed pharmaceutical companies in China's innovative drug research arena, with a customer retention rate of 100%, laying a solid foundation for the company's future expansion into new businesses such as life science insurance and further development of the pharmaceutical industry value chain. Looking to the future, SIPAI HEALTH's strategic direction is clear: it will continue to focus on corporate health insurance and enterprise health management, consolidating its competitive advantage in these areas while actively expanding into property insurance, life science insurance, and other diversified businesses to broaden its sources of income and services, accelerating its strategic upgrade towards becoming a "comprehensive enterprise risk management expert". This strategic path has been successful internationally. Major international insurance giants such as Marsh & McLennan (NYSE: MRSH) and AON (NYSE: AON) have developed a diversified business model covering risk management services, insurance brokerage, reinsurance brokerage, and more, providing comprehensive risk management solutions to enterprises, significantly improving customer loyalty and service efficiency. In 2026, SIPAI HEALTH has established three new business units - the Corporate Large Risk Management Division, the Reinsurance Division, and the Life Science Insurance Division, systematically laying out a diversified business matrix. Simultaneously, the company is actively expanding into international markets, cooperating with high-quality international insurance brokerage firms. In 2025, SIPAI HEALTH reached a strategic cooperation framework agreement with Gallagher, intending to cooperate in areas such as group life insurance, health insurance, and reinsurance. Gallagher's rich international insurance resources and service experience are expected to enhance SIPAI HEALTH's reinsurance service capabilities and help it explore international markets. In conclusion In the short term, SIPAI HEALTH's strategic transformation has led to a temporary decline in revenue but has resulted in a significant improvement in profitability, cash flow, and core business, validating the correctness of its transformation strategy. In the long run, by building an integrated ecosystem of "insurance, health, medicine, and wellness," the company has taken the lead in the blue ocean market of corporate health insurance and health management. With the continued elevation of commercial health insurance to a national strategic position, SIPAI HEALTH is poised to capitalize on its unique ecological advantages, unlocking a broader space for value creation in the future.